MapLight Therapeutics, Inc.
$28.34
▲
1.63%
2026-04-21 08:13:01
www.maplightrx.com
NMS: MPLT
Explore MapLight Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.28 B
Current Price
$28.34
52W High / Low
$31.13 / $12.24
Stock P/E
—
Book Value
$10.41
Dividend Yield
—
ROCE
-36.5%
ROE
-56.19%
Face Value
—
EPS
$-18.56
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
133
Beta
—
Debt / Equity
1.27
Current Ratio
20.01
Quick Ratio
20.01
Forward P/E
-7.15
Price / Sales
—
Enterprise Value
$877.46 M
EV / EBITDA
-5.21
EV / Revenue
—
Rating
Strong Buy
Target Price
$32.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Assembly Biosciences, Inc. | $28.13 | — | $446.22 M | — | -5.8% | -5.1% | $39.7 / $9.68 | $13.04 |
| 2. | Telomir Pharmaceuticals, Inc. | $1.48 | — | $49.85 M | — | -178.22% | -3.18% | $3.1 / $1.05 | $0.17 |
| 3. | IDEAYA Biosciences, Inc. | $33.6 | — | $2.95 B | — | -15.17% | -10.92% | $39.28 / $16.07 | $11.65 |
| 4. | Nektar Therapeutics | $100.35 | — | $2.87 B | — | -57.64% | -2.18% | $109 / $7.99 | $4.41 |
| 5. | Rhythm Pharmaceuticals, Inc. | $87.72 | — | $5.99 B | — | -51.31% | -90.45% | $122.2 / $55.31 | $2.07 |
| 6. | vTv Therapeutics Inc. | $37.75 | — | $157.78 M | — | -39.41% | -78.94% | $44 / $14 | $5.19 |
| 7. | Xencor, Inc. | $12.8 | — | $941.6 M | — | -22.77% | -14.07% | $18.69 / $6.92 | $8.84 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -83.38 M | -31.5 M | -22.78 M | -20.89 M |
| Net Profit | -79.55 M | -29.42 M | -21.23 M | -19.02 M |
| EPS in Rs | -1.87 | -0.69 | -0.5 | -0.45 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | — | — | — |
| Operating Profit | -169.08 M | — | — | — |
| Net Profit | -161.15 M | — | — | — |
| EPS in Rs | -3.8 | -2.96 | — | — |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 479.51 M | — | — | — |
| Total Liabilities | 21.14 M | 21.72 M | 20.13 M | 18.52 M |
| Equity | 458.37 M | 115.19 M | 71.28 M | 20.87 M |
| Current Assets | 324.67 M | — | — | — |
| Current Liabilities | 16.23 M | — | — | — |
Cash Flow
Last available yearly cash flow history
| 2025 | |
|---|---|
| Operating CF | -138.14 M |
| Investing CF | -323.21 M |
| Financing CF | 469.82 M |
| Free CF | -138.61 M |
| Capex | -0.47 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue Growth % | — | — | — |
| Earnings Growth % | — | — | — |
| Profit Margin % | — | — | — |
| Operating Margin % | — | — | — |
| Gross Margin % | — | — | — |
| EBITDA Margin % | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.